title: Vitamin K2 selectively induces apoptosis of blastic cells in myelodysplastic syndrome: flow cytometric detection of apoptotic cells using APO2.7 monoclonal antibody.
abstract: We have previously reported that vitamin K2 (VK2) but not VK1 has a potent apoptosis-inducing effect on freshly isolated leukemia cells from patients with various types of leukemia. By multi-color flow cytometric analysis using monoclonal antibody (mAb), APO2.7, which detects mitochondrial 7A6 antigen specifically expressed by cells undergoing apoptosis, we further investigated the apoptosis-inducing effect of VK2 on minor populations of leukemic blast cells in bone marrow from patients with myelodysplastic syndrome (MDS) and overt myeloid leukemia (post-MDS AML). Limiting dilution of CD95 (anti-Fas) mAb-treated apoptotic Jurkat cells with nonapoptotic CTB-1 cells revealed that APO2.7-positive Jurkat cells were consistently detectable by flow cytometry when present at levels of at least 5% in the CTB-1 suspension. In patient samples the gating area for leukemic clone was determined using cell surface antigen-specific mAbs conjugated with either fluorescein isothionate (FITC) or phycoerythrin (PE) and subsequently the cells stained with phycoerythrin cyanine (PE-Cy5)-conjugated APO2.7 mAb were assessed within the gating area of the leukemic clone for monitoring apoptosis. Treatment of the bone marrow mononuclear cells with 3-10 microM of VK2 (menaquinone-3, -4 and -5) in vitro potently induced apoptosis of the leukemic blast cells as compared with the untreated control cells in all 15 MDS patients tested. This effect was more prominent on blastic cells than that on mature myeloid cells such as CD34-/CD33+ gated cells. In addition, VK2 performed much less effectively on CD3-positive lymphoid cells. In contrast to VK2, VK1 did not show apoptosis-inducing activity. These data suggest that VK2 may be used for treatment of patients with MDS in blastic transformation.
authors.affiliation: 1st Department of Internal Medicine (Hematology/Oncology), Tokyo Medical College, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yaguchi
authors.forename: K
authors.initials: K
authors.lastname: Miyazawa
authors.forename: M
authors.initials: M
authors.lastname: Otawa
authors.forename: T
authors.initials: T
authors.lastname: Katagiri
authors.forename: J
authors.initials: J
authors.lastname: Nishimaki
authors.forename: Y
authors.initials: Y
authors.lastname: Uchida
authors.forename: O
authors.initials: O
authors.lastname: Iwase
authors.forename: A
authors.initials: A
authors.lastname: Gotoh
authors.forename: Y
authors.initials: Y
authors.lastname: Kawanishi
authors.forename: K
authors.initials: K
authors.lastname: Toyama
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D019169:Jurkat Cells / Q000187:drug effects; D008565:Membrane Proteins / Q000276:immunology; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D014812:Vitamin K / Q000031:analogs & derivatives / Q000494:pharmacology*
chemical_list: D000911:Antibodies, Monoclonal; D008565:Membrane Proteins; C102086:antigen 7A6; D014812:Vitamin K